Literature DB >> 24294355

Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice.

Hiroko Itagaki1, Kazuhiko Shimizu, Shunichi Morikawa, Kenji Ogawa, Taichi Ezaki.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH), appears to be increasingly common worldwide. Its histopathology and the effects of nutrition on liver function have not been fully determined. AIM: To elucidate the cellular mechanisms of NAFLD induced by a methionine-choline-deficient (MCD) diet in mice. Particular focus was placed on the role of phagocytic cells.
METHODS: Male C57BL/6 mice were fed an MCD diet for 30 weeks. A recovery model was also established wherein a normal control diet was provided for 2 weeks after a period of 8, 16, or 30 weeks.
RESULTS: Mice fed the MCD diet for ≥ 2 weeks exhibited severe steatohepatitis with elevated serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Steatohepatitis was accompanied by the infiltration of CD68-positive macrophages (Kupffer cells). The severity of steatohepatitis increased in the first 16 weeks but was seen to lessen by week 30. Fibrosis began to develop at 10 weeks and continued thereafter. Steatohepatitis and elevated serum hepatic enzyme concentrations returned to normal levels after switching the diet back to the control within the first 16 weeks, but fibrosis and CD68-positive macrophages remained.
CONCLUSIONS: The histopathological changes and irreversible fibrosis seen in this model were caused by prolonged feeding of an MCD diet. These results were accompanied by changes in the activity of CD68-positive cells with temporary elevation of CCL-2, MMP-13, and MMP-9 levels, all of which may trigger early steatohepatitis and late fibrosis through phagocytosis-associated MMP induction.

Entities:  

Keywords:  CD68 antigen; Kupffer cells; liver fibrosis; matrix metalloproteinase (MMP); mouse; non-alcoholic fatty liver disease (NAFLD)

Mesh:

Substances:

Year:  2013        PMID: 24294355      PMCID: PMC3843249     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice.

Authors:  Virginia Maina; Salvatore Sutti; Irene Locatelli; Matteo Vidali; Cristina Mombello; Cristina Bozzola; Emanuele Albano
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

3.  Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis.

Authors:  K Hironaka; I Sakaida; Y Matsumura; S Kaino; K Miyamoto; K Okita
Journal:  Biochem Biophys Res Commun       Date:  2000-01-07       Impact factor: 3.575

4.  Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients.

Authors:  Joong-Won Park; Gyu Jeong; Sang Jin Kim; Mi Kyung Kim; Sill Moo Park
Journal:  J Gastroenterol Hepatol       Date:  2007-04       Impact factor: 4.029

5.  NASH: A global health problem.

Authors:  Arun J Sanyal
Journal:  Hepatol Res       Date:  2011-07       Impact factor: 4.288

6.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

7.  Methionine deficiency and hepatic injury in a dietary steatohepatitis model.

Authors:  Helieh S Oz; Theresa S Chen; Manuela Neuman
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

Review 8.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

9.  Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model.

Authors:  Tatsuhiro Tsujimoto; Hideto Kawaratani; Toshiyuki Kitazawa; Toshiko Hirai; Hajime Ohishi; Mitsuteru Kitade; Hitoshi Yoshiji; Masahito Uemura; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

10.  Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice.

Authors:  Robert S McCuskey; Yoshiya Ito; Graham R Robertson; Margaret K McCuskey; Michael Perry; Geoffrey C Farrell
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

View more
  60 in total

1.  Hepatic HKDC1 Expression Contributes to Liver Metabolism.

Authors:  Carolina M Pusec; Adam De Jesus; Md Wasim Khan; Alexander R Terry; Anton E Ludvik; Kai Xu; Nicholas Giancola; Haaris Pervaiz; Emily Daviau Smith; Xianzhong Ding; Stephen Harrison; Navdeep S Chandel; Thomas C Becker; Nissim Hay; Hossein Ardehali; Jose Cordoba-Chacon; Brian T Layden
Journal:  Endocrinology       Date:  2019-02-01       Impact factor: 4.736

2.  Evaluation of Nonalcoholic Fatty Liver Disease in C57BL/6J Mice by Using MRI and Histopathologic Analyses.

Authors:  Jae-Eun Ryu; Woori Jo; Hyun-Ji Choi; Sungwoong Jang; Hyo-Ju Lee; Dong-Cheul Woo; Jeong Kon Kim; Kyung Won Kim; Eun Sil Yu; Woo-Chan Son
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

Review 3.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

4.  Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.

Authors:  Gabriella V Hernandez; Victoria A Smith; Megan Melnyk; Matthew A Burd; Kimberly A Sprayberry; Mark S Edwards; Daniel G Peterson; Darin C Bennet; Rob K Fanter; Daniel A Columbus; Juan P Steibel; Hunter Glanz; Chad Immoos; Margaret S Rice; Tasha M Santiago-Rodriguez; Jason Blank; Jennifer J VanderKelen; Christopher L Kitts; Brian D Piccolo; Michael R La Frano; Douglas G Burrin; Magdalena Maj; Rodrigo Manjarin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-31       Impact factor: 4.052

5.  Biomolecular Ultrasound Imaging of Phagolysosomal Function.

Authors:  Bill Ling; Justin Lee; David Maresca; Audrey Lee-Gosselin; Dina Malounda; Margaret B Swift; Mikhail G Shapiro
Journal:  ACS Nano       Date:  2020-09-14       Impact factor: 15.881

Review 6.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

7.  Publisher Correction: The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

8.  Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis.

Authors:  Hayley T Nicholls; Jason L Hornick; David E Cohen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-06       Impact factor: 4.052

Review 9.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

10.  Dietary methionine restriction: Effects on glucose tolerance, lipid content and micro-RNA composition in the muscle of rainbow trout.

Authors:  M N Latimer; B M Cleveland; P R Biga
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2017-10-31       Impact factor: 3.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.